Iovance Biotherapeutics

IOVA

Market cap $1.53B

SAN CARLOS, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced that senior leadership plans to present at the following upcoming conferences:

A relative unknown, if you don't watch the biotherapeutics industry, Iovance Biotherapeutics ( NASDAQ:IOVA ) surged 43% in the past week after reporting Q4 2025 earnings on February 24, pushing Reddit sentiment to 86 out of 100.

Iovance posts narrower Q4 loss as Amtagvi sales jump 33%. Shares soar on 50% ORR data and plans for registrational sarcoma study.

Iovance Biotherapeutics demonstrates improved Q4 results, with $87M revenue and a 50% gross margin (ex-D&A), but remains high-risk/high-reward. AMTAGVI drives IOVA's prospects, with a modeled $1.6B peak sales and first profit expected in 2028, yet manufacturing and adoption remain challenges. Their cash runway extends into Q3 2027, but dilution risk is material as AMTAGVI is unlikely to generate cash before then; ex-U.S. partnerships are a potential solution.

Iovance Biotherapeutics (NASDAQ: IOVA) shares are surging on Tuesday following the announcement of positive early data from a pilot clinical trial for its TIL cell therapy in advanced soft-tissue sarcomas.

Iovance Biotherapeutics, Inc. (IOVA) Q4 2025 Earnings Call Transcript

Iovance Biotherapeutics (IOVA) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.22. This compares to a loss of $0.26 per share a year ago.

Both Iovance Biotherapeutics IOVA and Rigel Pharmaceuticals RIGL are small-cap companies focused on the successful commercialization of their marketed products.

50% Objective Response Rate (ORR) in Advanced Sarcomas Significant Market Opportunity with More than 8,000 Patients Diagnosed Annually in the U.S. and Europe SAN CARLOS, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a commercial biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (TIL) therapies for patients with cancer, today announced positive early data from a pilot clinical trial led by Memorial Sloan Kettering Cancer Center (MSKCC) and supported by Iovance of lifileucel in patients with advanced (metastatic or unresectable) undifferentiated pleomorphic sarcoma (UPS) or dedifferentiated liposarcoma (DDLPS) who were refractory to at least one prior line of systemic therapy.

This biotech stock won approval for a cancer treatment a couple of years ago. That treatment is starting to generate revenue growth.